Member Info for Toukankahmoon

vs

you keep bringing up the virgilio sacchini interview but:

he approached cc after a convention

he had breast cancer patients cured of cancer following treatment with a ****tail including doxorubicin

a large proportion of those patients died in the weeks following of collateral damage to vital organs

alerted to ava6000’s unique targeting he saw this as an excellent alternative treatment

coincidentally p1a results had shown results for mid fap tumours like tnbc

virgilio sacchini was just parroting the specification of ava6000 in the context of how it would revolutionise treatment of his patients.

at that time none of his patients had been treated. they couldn’t have been unless there was some clandestine clinical trial taking place in parallel that we haven’t been told about.

we all want avacta to be successful, but trotting out this rubbish about virgilio sacchini really isn’t helping.

. . . and to you!

Also if that wasn’t enough there’s 🔥x 🧁s to be had tomorrow 😄

“Will be the last cheap drop by the MM’s while they can fill their boots with petty traders flogging last minute.”

Jeez how many rampers have written similar posts over the last years only to see the SP go even lower? It would be laughable if I wasn’t so far under water already.

Of course it was deleted. The hard truth is always deleted from this BB. Why spoil the baseless ramping.

VS

11 patients clearly isn’t enough

Jeez. Are you Icecool in disguise? When has a long period of silence ever been good for this share? Have you even read the communications from Avacta? Nothing will change until we get great P1b results. Your massive baseless ramping is positively depressing as the SP sinks.

Gubbie

I agree with your overall analysis

I just don’t see it happening as soon as you do.

I have been in since it looked like they were going to manufacture the best Covid test in the world and bought a couple of times since but not in the last two years. Certainly not in the fund raise last year. I’m averaging about 24p overall. But won’t be buying or selling any time soon

BenH

Ha ha ya got me🤣🤡🤣🤡

Defo Novartis and has been ever since CC took over. Just need those unexpected exceptional P1b results to be published.

Yeah “ no news is good news” like it has been every time over the past 5 years NOT

However I do agree that to sell now would be a poor decision. On the other hand, if you already have a substantial holding, buying right now is risky.

Watching

I’m getting worried. That’s the second time this year that I agree with you.

Gubbie have you escaped from the Avacta BB? That’s the sort of hopeful dreaming that normally takes place there. Or are you Apre in disguise?

ITO IPO are we talking about the £1 IPO or the more recent 9p IPO 🤣

It still amazes me how the clowns on here post their opinion as fact and then someone who actually knows what they are talking about blows them out the water.

I won’t embarrass them by naming names 🤣❤️

Aldebaran

I appreciate the positivity, but you see every little thing as a sign that something really positive is coming. Despite P1b results being months off 🤡

VS why? Is the truth too hard to swallow?

Bigears “She has nearly four years worth of positive in - clinic data in her handbag, yet she is incapable of selling it , she doesn’t possess the skillset.”. Or just possibly the data isn’t good enough yet. Certainly it isn’t consistent enough across a statistically significant number of patients. Hopefully P1b results will start to change that (or we might have to wait until P2). But CC can’t change that unless she makes stuff up🤡

. . . and none of them include an opinion in their posts . . . just sums up this BB

Folks

It isn’t doomed. There is an excellent upside. I expect to double my investment. Even though that would mean an SP of about £3 but unless you’ve got a hell of a lot at risk here, you aren’t going to be a millionaire. Sorry if that is a shock.

It is a bad idea to think that AVA6000 will take over the whole of the market that doxorubicin has at the moment. It doesn’t allow for competing treatments. Also any profit from AVA6000 will be ploughed back into R&D. There is little chance of Avacta distributing a decent dividend. That is what all the sky high valuations don’t take into account.

So Bigears you just want CC to make up stuff in order improve confidence in Avacta and boost SP and clinch the licensing of AVA6000. Even though she has published a timescale that reflects the results from P1b as being the pivotal point.

And they talk about AIM being thick as mince🤡

Regardless of the ongoing war on this BB, it is good news for breast cancer patients and a reminder that the world isn’t standing still waiting for Avacta. Let’s hope it doesn’t take 20 years to develop AVA6000 and get NICE approval.